pramipexole ER (CTC-413) / Chase Therap - LARVOL DELTA

A Study to Evaluate in Patients With Parkinsonian Type Disorders (clinicaltrials.gov) - P2 | N=24 | Active, not recruiting | Sponsor: Chase Therapeutics Corporation | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

A Study to Evaluate in Patients With Parkinsonian Type Disorders (clinicaltrials.gov) - P2 | N=24 | Active, not recruiting | Sponsor: Chase Therapeutics Corporation | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

A Study to Evaluate in Patients With Parkinsonian Type Disorders (clinicaltrials.gov) - P2 | N=24 | Active, not recruiting | Sponsor: Chase Therapeutics Corporation | Unknown status ➔ Active, not recruiting | Trial completion date: Mar 2020 ➔ Dec 2023 | Trial primary completion date: Dec 2019 ➔ Dec 2023

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

Chase Therapeutics Announces $20 Million Series B Financing to Advance Clinical Trials in Parkinson’s Disease and Major Depressive Disorder (Businesswire) - "Chase Therapeutics Corporation...today announced the completion of a milestone-based $20M Series B financing led by Chinalink Asia Holdings of Hong Kong....The proceeds of the Series B will support Phase 3 pivotal trials for CTC-501 for the treatment of Major Depressive Disorder (MDD) and CTC-413 for the treatment of Parkinson’s Disease (PD) as well as completion of the development and validation of a diagnostic product for Parkinson’s Disease."

Financing • CNS Disorders • Depression • Major Depressive Disorder • Parkinson's Disease